General Information
Version
6.3
Revision date
2023-11-27
Product name
Thrombin,Active,Human Plasma
REACH No
This
1.2.2. Uses advised against
For R&D use only. Not for pharmaceutical, household or other uses
Emergency telephone
+44 (0)870 8200418
Icons in SDS
Company Information
company name
Merck Life Science UK Limited
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H319, H334
Hazard statements
Code
Statements
H319
Causes serious eye irritation
Section 2
SECTION 2: Hazards identification
2.2 Label elements
Labelling
Signal word
Danger Danger
Hazard statements
H319 Causes serious eye irritation. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. Reduced Labeling (<= 125 ml) H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Precautionary statements
P261 Avoid breathing dust. P264 Wash skin thoroughly after handling. P280 Wear eye protection/ face protection. P284 Wear respiratory protection. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313 If eye irritation persists: Get medical advice/ attention. P261 Avoid breathing dust. P284 Wear respiratory protection.
Supplemental label elements
none none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
